Results 11 to 20 of about 75,183 (262)

Hepatitis B Vaccines [PDF]

open access: yesThe Journal of Infectious Diseases, 2021
Abstract Hepatitis B is caused by the hepatitis B virus (HBV), which infects the liver and may lead to chronic liver disease, including cirrhosis and hepatocellular carcinoma. HBV represents a worldwide public health problem, causing major morbidity and mortality.
Pattyn, Jade   +3 more
openaire   +4 more sources

Vaccine coverage, antibodies against measles, mumps, rubella, hepatitis B in inflammatory bowel disease and juvenile idiopathic arthritis children [PDF]

open access: diamondWorld J Clin Pediatr
Elizaveta Makarova   +9 more
openalex   +2 more sources

Health disparities in chronic liver disease

open access: yesHepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian   +3 more
wiley   +1 more source

Identification of novel neutralizing determinants for protection against HCV

open access: yesHepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua   +12 more
wiley   +1 more source

Leveraging corona virus disease 2019 vaccination to promote hepatitis C screening

open access: yesHepatology Communications, EarlyView., 2022
Abstract Health care initiatives, such as hepatitis C virus (HCV) screening, have been greatly overshadowed by the corona virus disease 2019 (COVID‐19) pandemic. However, COVID‐19 vaccination programs also provide an opportunity to engage with a high volume of people in a health care setting.
Aaron Vanderhoff   +17 more
wiley   +1 more source

Hepatitis B vaccination [PDF]

open access: yesBMJ, 2007
Hepatitis B virus is a substantial threat to global health, with 360 million people chronically infected and more than 500 000 deaths each year from fulminant hepatitis, cirrhosis, and liver cancer.1 2 After a call by the World Health Organization for the global introduction of vaccine prevention programmes by 1997,3 82% of countries in the world had ...
openaire   +4 more sources

Systematic Review of Postvaccination Ocular Adverse Events: A Comprehensive Analysis of Published Reports. [PDF]

open access: yesJ Med Virol
ABSTRACT Ocular adverse events following COVID‐19 vaccination are well described; however, systematic analyses of non‐COVID antiviral vaccines remain limited. This review aimed to evaluate ocular complications associated with non‐COVID antiviral immunizations, including influenza, varicella‐zoster (VZV), human papillomavirus (HPV), and hepatitis B (HBV)
Zou Y   +5 more
europepmc   +2 more sources

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

open access: yesAdvanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth   +2 more
wiley   +1 more source

Nano‐ and Micro‐Sized Solid Materials Used as Antiviral Agents

open access: yesAdvanced Functional Materials, EarlyView.
Due to the rise of viral infections in humans and possible viral outbreaks, the use of nano‐ or micro‐sized materials as antiviral agents is rapidly increasing. This review explores their antiviral properties against RNA and DNA viruses, either as a prevention or a treatment tool, by delving into their mechanisms of action and how to properly assess ...
Orfeas‐Evangelos Plastiras   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy